---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-205124"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:23:41.799133+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q1 net loss $97.4M; cash $866.4M to fund into 2028; NDA for bezuclastinib in GIST under FDA review

## Summary
- Net loss $97.4M for Q1 2026 vs $72.0M Q1 2025; R&D spend $75.4M, G&A $28.2M.
- Cash, equivalents and marketable securities $866.4M as of March 31, 2026, expected to fund operations into 2028.
- FDA has accepted NDA for bezuclastinib in NonAdvSM (PDUFA Dec 30, 2026); NDA for GIST submitted under RTOR with Breakthrough Therapy designation.
- Pivotal Phase 3 PEAK trial data in GIST selected for oral presentation at 2026 ASCO annual meeting on May 30.
- Inducement grants of options for 62,600 shares and 48,600 RSUs awarded to seven new employees on April 29, 2026.

## SEC filing metadata
- accession: 0001193125-26-205124
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/0001193125-26-205124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-205124
- JSON: https://secwatch.observer/filing/0001193125-26-205124.json
- Plain text: https://secwatch.observer/filing/0001193125-26-205124.txt

## Source-grounded claims
- claim_id: 60bc64785ceecbcb7a044334077e4dadde7cb7e9
  claim: Cogent Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $97.4 million for the first quarter of 2026 compared to a net loss of $72.0 million for the first quarter o.
  evidence_excerpt: On May 5, 2026, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/0001193125-26-205124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.